Department of Defense awards Entegrion $8.2M to develop dried plasma

Life sciences company Entegrion has won a two-year, $8.2 million contract from the U.S. Department of Defense to continue development of a dried human plasma product that can be used for transfusions.
The Research Triangle Park-based company will deploy the funds to “scale-up” production and to develop efficient manufacturing processes for the production of the dried plasma, which has a longer shelf life than liquid plasma and does not have to be refrigerated, making it much easier to transport.
“This technology will help improve the safety and availability of blood and blood products for transfusion in domestic and global health applications, and we are pleased to see the military’s continued confidence and investment commitment to the technology,” said Joseph A. DaCorta, vice president and chief technology officer of Entegrion.
Entegrion develops products that help to control bleeding. Human blood contains proteins and clotting factors, is often used in situations in which patients suffer severe bleeding. Entegrion’s dried plasma product is designed to be quickly rehydrated, offering a time advantage of fresh frozen plasma, which can take time to thaw.

Hemostasis Blog Valued Resource!

The Medical Hemostat Blog has gained wide geographical and company interest. You are welcome to contact me at hemostatguy@gmail.com. I also have consulted with market research firms such as Frost and Sullivan amongst other research organisations.

While I address a need for comprehensive information regarding hemostasis, I am pleased to announce our top, google analytics identified company visitors:

1. Johnson & Johnson
2. CryoLife
3. Baxter
4. Trauma Cure
5. Tyco
6. Zymogenetics
7. Medafor
8. Hemcon
9. King Pharmaceuticals
10. Entegrion
11. St. Jude
12. Aventis Behring

I would appreciate any contributions readers care to send and am actively seeking projects in this field.

Thank You for following the Blog.

HG

Hemostasis, Control of Bloodloss - War, EMS, Military,First Resonders, Ambulance

U.S. Navy Awards Entegrion Contracts for $4 Million

August 6, 2009 -- The U.S. Navy has awarded two additional contracts to the life sciences company Entegrion, Inc., for implementation of the company's proprietary technologies to improve the safety and availability of blood-derived products for treating combat injuries. Recent medical research has demonstrated that such blood component therapy is essential in responding to traumatic injury, especially on the battlefield. The base contracts total about $4 million, with an additional $2 million for expanded research.

"Our military does a heroic job in overcoming the logistical challenges of ensuring that critically needed blood supplies are available when and where they are needed," said Joseph DaCorta, Entegrion's Chief Technology Officer. "Trends in clinical practice are moving toward earlier and more aggressive use of blood components after serious injury. However, availability of such therapies is often seriously restricted by shelf-life limitations and storage requirements. Technologies like ours to produce blood-derived products that can be stored for longer periods, do not require refrigeration, and have fewer pathogens will support both military and civilian medical operations by ensuring both the safety and timely availability of blood products to treat serious injuries, particularly in remote and austere areas."

The first of the new contracts is for advanced development of Entegrion's Stasix®, a dehydrated platelet-derived hemostatic agent that can be reconstituted and transfused when needed for the control of non-compressible internal bleeding. The second contract is for advanced development of Entegrion's product, Resusix®, a dehydrated, pathogen-reduced, fresh human plasma for infusion in trauma patients to expand blood volume, correct abnormal coagulation function, and support hemostasis.

"We are honored to have been chosen by the Navy to assist them in meeting these critical requirements. For Entegrion, this represents the fourth major contract for such work over the last six years. We remain totally committed to building on our track record of providing timely and effective R&D to deliver these much needed therapeutics to both our military and the civilian markets that will follow," said Stan Eskridge, Chief Executive Officer of Entegrion.

Entegrion

Just received this video to share with you of Entegrion created Stasilon and its mode of action.

Entegrion achieve FDA approval

Entegrion, Inc., a privately owned life sciences product development company specializing in technologies for hemorrhage control, resuscitation, and tissue repair, announced that it has received 510(k) market approval from the U. S. Food and Drug Administration (FDA) for its hemostatic medical textile technology. The first application of the technology is Stasilon FR – hemostatic wound dressings for first responders. This market includes EMS workers, police officers, emergency personnel and fire fighters. The Stasilon FR – hemostatic wound dressing was approved by the FDA for use by medical professionals under prescription and “over-the-counter” by consumers to control bleeding resulting from “minor cuts and abrasions” as well as “lacerations, punctures and incisions.” Pending acceptance of an amendment to the FDA approval, a second version of the technology will be implemented as Stasilon OR – hemostatic surgical pads.
Entegrion 510K available HERE

Blood-staunching bandages

Conventional gauze bandages do not work well enough because, although they absorb blood, they do not prevent its flow. Thomas Fischer and colleagues at the Francis Owen Blood Research Laboratory at the University of North Carolina at Chapel Hill think they may have the solution.
His team has discovered that bandages made from about 65% glass fibre and 35% bamboo fibre not only absorb blood but also stimulate the body's ability to staunch the flow by triggering the release of blood-clotting factors such as thrombin or fibrinogen. They say the bandages work even better if they are themselves impregnated with blood-clotting factors.
Given the number of military casualties in Afghanistan and Iraq this is an idea that could well be fast-tracked. The idea is part-owned by a company called Entegrion, which was co-founded by Fischer. So all the pieces are in place for the bandages to be commercialised soon.
Read the full patent application for blood-staunching bandages.